Reviewer’s report

Title: Phase II randomized study of neoadjuvant METformin plus letrozole vs placebo plus letrozole for estrogen receptor positive pOstmenopausal bReast cancer (METEOR)

Version: 3 Date: 25 October 2013

Reviewer: Marco Alessandro A Pierotti

Reviewer’s report:

This is a randomized phase II study with activity as a primary end point. The number of centers involved is reasonable to recruit a sufficient number of patients. The translational project is technically very ambitious, even if the panel tested on tissue microarrays is not described.

Treatment is proper even if six months of aromatase inhibitors in patients with high grade or with Ki 67 > 30% can be argued as compared to chemotherapy.

The timing of dose increasing of metformin is not described.

Level of interest: An article of outstanding merit and interest in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

No competing interests